

# Biotransformations from and to methylated flavonoids

## *Subtitle*

Benjamin Weigel  
Leibniz-Institute of Plant Biochemistry  
Department of Bioorganic Chemistry  
Weinberg 3  
06120 Halle(Saale)  
May 27, 2015

Advisor: Prof. Dr. Ludger A. Wessjohann  
wessjohann@ipb-halle.de  
+49 (345) 5582-1301

noch nicht bekannt

1 **Contents**

2	<b>Notes of Revisors</b>	viii
3	<b>I Preface</b>	1
4	<hr/>	
5	<b>1 Abstracts</b>	2
6	1.1 English Abstract . . . . .	2
7	1.2 Deutsche Zusammenfassung . . . . .	2
8	<b>II Thesis</b>	3
9	<hr/>	
10	<b>2 Introduction</b>	4
11	2.1 Natural products and secondary metabolites . . . . .	4
12	2.1.1 General. . . . .	4
13	2.1.2 Classes of natural products . . . . .	4
14	2.2 Alkylating reactions in nature . . . . .	4
15	2.2.1 Methylation . . . . .	4
16	2.2.2 Prenylation . . . . .	4
17	2.2.3 Glycosylation . . . . .	5
18	2.3 Usage and expansion of natures reaction toolbox . . . . .	5
19	2.3.1 Terpene synthases and elongases . . . . .	5
20	2.3.2 Methyl transferases. . . . .	5
21	2.3.3 Glycosyl transferases. . . . .	5
22	2.3.4 Other important enzymes in biotech research. . . . .	5
23	2.4 Conclusion . . . . .	5

1	<b>3 Material And Methods</b>	6
2	3.1 Materials . . . . .	6
3	3.1.1 Chemicals . . . . .	6
4	3.1.2 Commonly used solutions and buffers . . . . .	6
5	3.1.3 Culture media used to grow bacteria . . . . .	7
6	3.1.4 Bacterial strains . . . . .	7
7	3.1.5 Plasmids . . . . .	9
8	3.1.6 Oligonucleotides and synthetic genes . . . . .	9
9	3.1.7 Instruments . . . . .	10
10	3.1.8 Software . . . . .	10
11	3.2 Molecular Biology . . . . .	10
12	3.2.1 Golden Gate Cloning . . . . .	11
13	3.2.2 Subcloning of genes . . . . .	11
14	3.2.3 Transformation of electrocompetent <i>Agrobacterium tumefaciens</i>	
15	cells. . . . .	12
16	3.3 Treatment of plant material . . . . .	12
17	3.3.1 Infiltration of <i>Nicotiana benthamiana</i> . . . . .	12
18	3.3.2 Plant material harvest . . . . .	12
19	3.3.3 Extraction of flavonoids from <i>N. benthamiana</i> leaves . . . . .	12
20	3.4 Protein biochemistry . . . . .	13
21	3.4.1 Determination of protein concentration . . . . .	13
22	3.4.2 Protein production test (expression test) . . . . .	13
23	3.4.3 Protein subfractionation . . . . .	14
24	3.4.4 Protein sample concentration by TCA precipitation . . . . .	14
25	3.4.5 Preparation of periplasmic protein . . . . .	15
26	3.4.6 Discontinuous SDS-polyacrylamide gel electrophoresis (SDS-	
27	PAGE) . . . . .	15
28	3.4.7 Buffer change of protein samples . . . . .	16
29	3.4.8 Production of recombinant protein . . . . .	16
30	3.4.9 Preparation of inclusion bodies (IBs). . . . .	17
31	3.4.10 Purification of His-tagged proteins using immobilized metal	
32	affinity chromatography (IMAC) . . . . .	17
33	3.4.11 Refolding of SOMT-2 on a micro scale using design of experi-	
34	ments (DoE) . . . . .	18
35	3.4.12 Enzymatic production of SAM and SAE . . . . .	20
36	3.5 Crystallographic Procedures . . . . .	20
37	3.5.1 Crystallization of proteins . . . . .	21
38	3.5.2 Data collection and processing . . . . .	22
39	3.5.3 Structure solution. . . . .	22
40	3.5.4 Model building, refinement and validation. . . . .	23

1	3.5.5 <i>In silico</i> substrate docking . . . . .	23
2	3.6 Analytics . . . . .	23
3	3.6.1 Recording of growth curves . . . . .	23
4	3.6.2 <i>In vitro</i> determination of glucose . . . . .	24
5	3.6.3 <i>In vitro</i> O-methyl transferase (O-MT) assay . . . . .	24
6	3.6.4 Photospectrometric assay for the methylation of catecholic moi-	
7	eties. . . . .	26
8	3.6.5 Concentration of SOMT-2 using hydrophobic interaction chro-	
9	matography (HIC) . . . . .	28
10	3.6.6 Analytical gel filtration. . . . .	28
11	3.6.7 Binding experiments using Isothermal Titration Calorimetry	
12	(ITC) . . . . .	28
13	3.6.8 High-performance liquid chromatography (HPLC) analytics .	29
14	3.6.9 liquid chromatography coupled mass-spectrometry (LC/MS)	
15	measurements. . . . .	29
16	<b>4 Evaluation of PFOMT towards the acceptance of long-chain SAM</b>	
17	<b>analogues</b> . . . . .	30
18	4.1 Introduction . . . . .	30
19	4.2 Substrate binding studies using ITC. . . . .	30
20	4.3 Determination of the structure of <i>apo</i> -PFOMT. . . . .	30
21	4.3.1 PFOMT activity in deep eutectic solvents (DES) / Solubility-	
22	enhancing effects of DES. . . . .	30
23	4.4 Study of variants for long-chain alkylations . . . . .	30
24	4.4.1 PFOMT-Paper (DIM) . . . . .	30
25	4.4.2 Dockings??? . . . . .	30
26	4.5 Colclusion/Discussion . . . . .	30
27	<b>5 Enzymatic methylation of Non-catechols</b> . . . . .	31
28	5.1 Introduction . . . . .	31
29	5.2 SOMT-2. . . . .	31
30	5.2.1 In vivo methylation studies using <i>N. benthamiana</i> . . . . .	31
31	5.2.2 In vivo studies in <i>E. coli</i> . . . . .	31
32	5.2.3 In vitro studies using recombinantly produced SOMT-2 . . . . .	31
33	5.3 PFOMT . . . . .	31
34	5.3.1 Acidity and Nucleophilicity of phenolic hydroxyl-groups . . .	31
35	5.3.2 pH-Profiles of PFOMT-catalysis . . . . .	31
36	5.3.3 Influence of Mg <sup>2+</sup> on PFOMT activity . . . . .	31
37	5.4 Consensus or Bioinformatic points-of-view (COMT)??? . . . . .	31
38	5.5 Conclusion/Discussion . . . . .	31

1	<b>6 Development of an whole cell methyl transferase screening sys-</b>	
2	<b>tem</b>	32
3	6.1 Introduction . . . . .	32
4	6.2 Theoretical considerations / design of system . . . . .	32
5	6.3 Detectability of <i>S</i> -adenosyl-L-homocysteine (SAH) . . . . .	32
6	6.4 Usage of the <i>lsr</i> -promoter for true autoinduction . . . . .	32
7	6.5 Conclusion/Discussion . . . . .	32
8	<b>7 DES in protein crystallography</b>	33
9	7.1 Introduction . . . . .	33
10	7.2 Solubility enhancement of hydrophobic substances by addition of	
11	DES . . . . .	33
12	7.3 Enzymatic <i>O</i> -methylation in DES . . . . .	33
13	7.4 DES as precipitants in protein crystallization . . . . .	33
14	7.5 Conclusion/Discussion . . . . .	33
15	<b>8 Acknowledgements</b>	34
16	<b>III Appendix</b>	35
17		
18	<b>A Figures</b>	36
19	<b>B Tables</b>	37
20	<b>C Affidavit</b>	39
21	<b>Acronyms</b>	45
22	<b>Glossary</b>	48





1 **List of Figures**

2	3.1	Oxidation of the reporter substrate <i>o</i> -dianisidine. Consecutive	
3		one-electron transfers lead to the fully oxidized diimine form of	
4		<i>o</i> -dianisidine. The first electron transfer is believed to produce a charge	
5		transfer complex intermediate. [23, 9] . . . . .	25
6	3.2	Calibration curves of different relative compositions of ferulic acid to	
7		caffeic acid, that were taken as described in 3.6.4. The total concen-	
8		tration was always 0.4 mM. At lower pH values around 4, the method	
9		seems to overestimate the concentration of caffeic acid. However, the	
10		slope of the curves stays the same. . . . .	27
11	A.1	Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean com-	
12		modo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus	
13		et magnis dis parturient montes, nascetur ridiculus mus. Donec quam	
14		felis, ultricies nec, pellentesque eu, pretium quis, sem. . . . .	36

<sup>1</sup> **List of Tables**

<sup>2</sup>	3.1 NADES-mixtures used within this work. . . . .	7
<sup>3</sup>	3.3 Plasmids used in this work. . . . .	9
<sup>4</sup>	3.4 Primers used in this work. Recognition sites for endonucleases are	
<sup>5</sup>	underlined. Positions used for site directed mutagenesis are in lower	
<sup>6</sup>	case font. . . . .	9
<sup>7</sup>	3.6 Calculated extinction coefficients of proteins used in this work.. . . .	13
<sup>8</sup>	3.7 Factors used in the construction of the FFD. . . . .	18
<sup>9</sup>	3.8 Experimental design matrix for the FFD. . . . .	19
<sup>10</sup>	B.1 Overview over the constructs produced for the present thesis. Each step	
<sup>11</sup>	during the production of the construct is given in the workflow steps	
<sup>12</sup>	column. Primers ( <i>italic font</i> ) or restriction sites used during each step	
<sup>13</sup>	are displayed in parenthesis. . . . .	38

<sup>1</sup> **Notes of Revisors**

<sup>2</sup>	 BWEIGEL: Überprüfen! . . . . .	16
<sup>3</sup>	 BWEIGEL: To introduction . . . . .	21
<sup>4</sup>	 BWEIGEL: Lysozym struktur . . . . .	22
<sup>5</sup>	 BWEIGEL: nochmal auseinanderklamüsern wegen den konzentratio-	
<sup>6</sup>	nen und eingesetzten enzyymmengen... . . . .	24



1

2

# I

# Preface

# 1 Abstracts

## 1.1 English Abstract

Test Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut purus elit, vestibulum ut, placerat ac, adipiscing vitae, felis. Curabitur dictum gravida mauris. Nam arcu libero, nonummy eget, consectetur id, vulputate a, magna. Donec vehicula augue eu neque. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Mauris ut leo. Cras viverra metus rhoncus sem. Nulla et lectus vestibulum urna fringilla ultrices. Phasellus eu tellus sit amet tortor gravida placerat. Integer sapien est, iaculis in, pretium quis, viverra ac, nunc. Praesent eget sem vel leo ultrices bibendum. Aenean faucibus. Morbi dolor nulla, malesuada eu, pulvinar at, mollis ac, nulla. Curabitur auctor semper nulla. Donec varius orci eget risus. Duis nibh mi, congue eu, accumsan eleifend, sagittis quis, diam. Duis eget orci sit amet orci dignissim rutrum.

## 1.2 Deutsche Zusammenfassung

Nam dui ligula, fringilla a, euismod sodales, sollicitudin vel, wisi. Morbi auctor lorem non justo. Nam lacus libero, pretium at, lobortis vitae, ultricies et, tellus. Donec aliquet, tortor sed accumsan bibendum, erat ligula aliquet magna, vitae ornare odio metus a mi. Morbi ac orci et nisl hendrerit mollis. Suspendisse ut massa. Cras nec ante. Pellentesque a nulla. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Aliquam tincidunt urna. Nulla ullamcorper vestibulum turpis. Pellentesque cursus luctus mauris.



# Thesis

1

2

## <sup>1</sup> 2 Introduction

<sup>2</sup> Some introductory text

### <sup>3</sup> 2.1 Natural products and secondary metabolites

#### <sup>4</sup> 2.1.1 General

#### <sup>5</sup> 2.1.2 Classes of natural products

##### <sup>6</sup> Terpenoids and Steroids

<sup>7</sup> ... here is some text

##### <sup>8</sup> Polyketides and non-ribosomal peptides

<sup>9</sup> ... here is some text

##### <sup>10</sup> Alkaloids

<sup>11</sup> ... here is some text

##### <sup>12</sup> Phenylpropanoids

<sup>13</sup> ... here is some text

### <sup>14</sup> 2.2 Alkylating reactions in nature

#### <sup>15</sup> 2.2.1 Methylation

#### <sup>16</sup> 2.2.2 Prenylation

<sup>1</sup> **2.2.3 Glycosylation**

<sup>2</sup> **2.3 Usage and expansion of natures reaction tool-**  
<sup>3</sup> **box**

<sup>4</sup> **2.3.1 Terpene synthases and elongases**

<sup>5</sup> **2.3.2 Methyl transferases**

<sup>6</sup> **2.3.3 Glycosyl transferases**

<sup>7</sup> **2.3.4 Other important enzymes in biotech research**

<sup>8</sup> **BMVOs**

<sup>9</sup> **Esterases/Lipases**

<sup>10</sup> **Oxidases**

<sup>11</sup> **Lyases**

<sup>12</sup> **Transaminases**

<sup>13</sup> **2.4 Conclusion**

<sup>14</sup> **C**

# 3 Material And Methods

Within this section percentages refer to volume per volume (v/v) percentages unless otherwise specified.

## 3.1 Materials

### 3.1.1 Chemicals

Enzymes and buffers used for molecular cloning were obtained from Life Technologies (Darmstadt, Germany), unless otherwise noted. Flavonoid HPLC standards were purchased from Extrasynthese (Genay, France). Deuterated solvents were aquired from Deutero GmbH (Kastellaun, Germany). Solvents, purchased from VWR (Poole, England), were distilled in-house before use. All other chemicals were obtained from either Sigma-Aldrich (Steinheim, Germany), Applichem (Darmstadt, Germany), Carl Roth (Karlsruhe, Germany) or Merck (Darmstadt, Germany).

### 3.1.2 Commonly used solutions and buffers

50× 5052	25 % glycerol, 2.5 % (w/v) glucose, 10 % (w/v) α-lactose
binding buffer	50 mM Tris/HCl, 500 mM NaCl, 10 % glycerol, 2.5 mM imidazole pH 7
elution buffer	50 mM Tris/HCl, 500 mM NaCl, 10 % glycerol, 250 mM imidazole pH 7
lysis buffer	50 mM Tris/HCl, 500 mM NaCl, 10 % glycerol, 2.5 mM imidazole, 0.2 % Tween-20 pH 7
1 M MMT pH 4 (10×)	26.8 g/l L-malic acid, 78.1 g/l MES, 26.8 g/l Tris, 2.1 % 10 M HCl
1 M MMT pH 9 (10×)	26.8 g/l L-malic acid, 78.1 g/l MES, 26.8 g/l Tris, 6.7 % 10 M NaOH
20× NPS	1 M Na <sub>2</sub> HPO <sub>4</sub> , 1 M KH <sub>2</sub> PO <sub>4</sub> , 0.5 M (NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub>

1 M SSG pH 4 (10×)	14.8 g/l succinic acid, 60.4 g/l NaH <sub>2</sub> PO <sub>4</sub> · H <sub>2</sub> O, 32.8 g/l glycine, 0.4 % 10 M NaOH
1 M SSG pH 10 (10×)	14.8 g/l succinic acid, 60.4 g/l NaH <sub>2</sub> PO <sub>4</sub> · H <sub>2</sub> O, 32.8 g/l glycine, 10.3 % 10 M NaOH
5× SDS sample buffer	10 % (w/v) SDS, 10 mM β-mercaptoethanol, 20 % glycerol, 0.2 M Tris/HCl pH 6.8, 0.05 % (w/v) bromophenolblue
1000× trace elements	50 mM FeCl <sub>3</sub> , 20 mM CaCl <sub>2</sub> , 10 mM MnCl <sub>2</sub> , 10 mM ZnSO <sub>4</sub> , 2 mM CoCl <sub>2</sub> , 2 mM CuCl <sub>2</sub> , 2 mM NiCl <sub>2</sub> , 2 mM Na <sub>2</sub> MoO <sub>4</sub> , 2 mM Na <sub>2</sub> SeO <sub>3</sub> , 2 mM H <sub>3</sub> BO <sub>3</sub>

<sup>1</sup> **Preparation of natural deep eutectic solvent (NADES)**

<sup>2</sup> NADES were prepared by adding each component in a round-bottom flask with  
<sup>3</sup> a stirrer and stirring the mixture at 50 °C with intermittent sonication treatments  
<sup>4</sup> until a clear solution was obtained.

*Table 3.1.: NADES-mixtures used within this work.*

name	composition	mole ratio	mass fraction (w/w)
PCH	propane-1,2-diol	1:1:1	0.326
	choline chloride		0.597
	water		0.077
GCH	D-glucose	2:5:5	0.314
	choline chloride		0.608
	water		0.078

<sup>5</sup> **3.1.3 Culture media used to grow bacteria**

LB-medium	10 g/l NaCl, 10 g/l tryptone, 5 g/l yeast extract, pH 7.5
LB-agar	LB + 1.5 % (w/v) agar-agar
TB-medium	12 g/l tryptone, 24 g/l yeaxst extract, 0.4 % glycerol, 72 mM K <sub>2</sub> HPO <sub>4</sub> , 17 mM KH <sub>2</sub> PO <sub>4</sub>
ZY	10 g/l tryptone, 5 g/l yeast extract
ZYP-5052	volume fraction (v/v): 0.928 ZY, 0.05 20× NPS, 0.02 50× 5052, 0.002 1 M MgSO <sub>4</sub> , 0.0002 1000× trace elements

<sup>6</sup> **3.1.4 Bacterial strains**

<sup>1</sup> *E.coli*

BL21(DE3)	F <sup>-</sup> <i>ompT hsdSB(r<sub>B</sub><sup>-</sup>,m<sub>B</sub><sup>-</sup>) gal dcm</i> λ(DE3) Invitrogen, Karlsruhe (Germany)
C41(DE3)	F <sup>-</sup> <i>ompT hsdSB(r<sub>B</sub><sup>-</sup>,m<sub>B</sub><sup>-</sup>) gal dcm</i> λ(DE3) Lucigen, Wisconsin (USA)
C43(DE3)	F <sup>-</sup> <i>ompT hsdSB(r<sub>B</sub><sup>-</sup>,m<sub>B</sub><sup>-</sup>) gal dcm</i> λ(DE3) Lucigen, Wisconsin (USA)
DH5α	F <sup>-</sup> Φ80 <i>lacZ</i> ΔM15 Δ( <i>lacZYA-argF</i> ) U169 <i>recA1 endA1 hsdR17(r<sub>K</sub><sup>-</sup>m<sub>K</sub><sup>+</sup>) phoA supE44 λ<sup>-</sup> thi-1 gyrA96 relA1</i> Invitrogen, Karlsruhe (Germany)
JM110	<i>rpsL thr leu thi lacY galK galT ara tonA tsx dam dcm glnV44</i> Δ( <i>lac-proAB</i> ) e14- [F' <i>traD36 proAB<sup>+</sup> lacI<sup>q</sup> lacZ</i> ΔM15] <i>hsdR17(r<sub>K</sub><sup>-</sup>m<sub>K</sub><sup>+</sup>)</i> Martin-Luther-University Halle-Wittenberg
JW1593 (BW25113 derivative)	<i>rrnB</i> Δ <i>lacZ</i> 4787 <i>HsdR</i> 514 Δ( <i>araBAD</i> )568 <i>rph-1</i> Δ <i>ydgG</i> (Kan <sup>R</sup> ) Keio Collection, National Institute of Genetics (Japan)
MG1655	F <sup>-</sup> λ <sup>-</sup> <i>ilvG<sup>-</sup> rfb-50 rph-1</i> DSMZ, Hamburg (Germany)
One Shot TOP10	F <sup>-</sup> Φ80 <i>lacZ</i> ΔM15 Δ( <i>mrr-hsdRMS-mcrBC</i> ) <i>recA1 endA1 mcrA</i> Δ <i>lacX74 araD139</i> Δ( <i>ara-leu</i> )7697 <i>galU galK rpsL</i> (Str <sup>R</sup> ) λ <sup>-</sup> <i>nupG</i> Invitrogen, Karlsruhe (Germany)
Origami(DE3)	Δ( <i>ara-leu</i> )7697 Δ <i>lacX74</i> Δ <i>phoA Pvull</i> <i>phoR araD139 ahpC galE galK rpsL</i> F'[ <i>lac + lacI q pro</i> ] (DE3) <i>gor522::Tn10 trxB</i> (Kan <sup>R</sup> , Str <sup>R</sup> , Tet <sup>R</sup> ) Novagen, Wisconsin (USA)
Rosetta(DE3)	F <sup>-</sup> <i>ompT hsdSB(r<sub>B</sub><sup>-</sup>,m<sub>B</sub><sup>-</sup>) gal dcm</i> λ(DE3) pRARE (Cam <sup>R</sup> ) Novagen, Wisconsin (USA)
Rosetta(DE3) pLysS	F <sup>-</sup> <i>ompT hsdSB(r<sub>B</sub><sup>-</sup>,m<sub>B</sub><sup>-</sup>) gal dcm</i> λ(DE3) pLysSRARE (Cam <sup>R</sup> ) Novagen, Wisconsin (USA)
T7 Express	<i>fhuA2 lacZ::T7 gene1 [lon] ompT gal sulA11 R(mcr-73::miniTn10-Tet<sup>S</sup>)2 [dcm] R(zgb-210::Tn10-Tet<sup>S</sup>) endA1</i> Δ( <i>mcrC-mrr</i> )114::IS10 NEB, Massachusetts (USA)

<sup>2</sup> *Agrobacterium tumefaciens*

GV3101	chromosomal background: C58, marker gene: <i>rif</i> , Ti-plasmid: cured, opine: nopaline Sylvestre Marillonet, IPB
--------	--



3.1.5 Plasmids

Table 3.3.: Plasmids used in this work.

name	supplier/source
pACYCDuet-1	Merck, Darmstadt (Germany)
pCDFDuet-1	Merck, Darmstadt (Germany)
pET-20b(+)	Merck, Darmstadt (Germany)
pET-28a(+)	Merck, Darmstadt (Germany)
pET-32a(+)	Merck, Darmstadt (Germany)
pET-41a(+)	Merck, Darmstadt (Germany)
pQE30	QIAGEN, Hilden (Germany)
pUC19	Invitrogen, Karlsruhe (Germany)

3.1.6 Oligonucleotides and synthetic genes

Oligonucleotides and primers were ordered from Eurofins Genomics (Ebersberg, Germany). The purity grade was *high purity salt free* (HPSF). Synthetic genes or gene fragments were obtained from GeneArt® (Life Technologies, Darmstadt, Germany) or Eurofins Genomics (Ebersberg, Germany).

Table 3.4.: Primers used in this work. Recognition sites for endonucleases are underlined. Positions used for site directed mutagenesis are in lower case font.

name	sequence (5'→3')	cloning site
somt1	TTG <u>AAG ACA</u> AAA TGG CTT CTT CAT TAA ACA ATG GCC G	BpiI
somt2	TTG <u>AAG ACA</u> AGG ACA CCC CAA ATA CTG TGA GAT CTT CC	BpiI
somt3	TTG <u>AAG ACA</u> AGT CCT TAG GAA CAC CTT TCT GGG AC	BpiI
somt4	TTG <u>AAG ACA</u> AAA GCT CAA GGA TAG ATC TCA ATA AGA GAC	BpiI
pfomt1.fw	CAG AGA GGC cTA TGA GAT TGG CTT GC	
pfomt1.rv	GCA AGC CAA TCT CAT AgG CCT CTC TG	
pfomt2.fw	<u>CAT ATG</u> GAT TTT GCT GTG ATG AAG CAG GTC	NdeI
pfomt2.rv	<u>GAA TTC</u> AAT AAA GAC GCC TGC AGA AAG TG	EcoRI
pRha1.fw	CTC TAG <u>CAG ATC</u> <u>TCG</u> GTG AGC ATC ACA TCA CCA CAA TTC	BglII
pRha1.rv	CAA TTG <u>AGG ATC</u> <u>CCC</u> ATT TTA ACC TCC TTA GTG	BamHI
pUC1.fw	GCG TAT TGG Gag aTC TTC CGC TTC CTC	
pUC1.rv	GAG GAA GCG GAA GAt ctC CCA ATA CGC	

3.1.7 Instruments

CD-spectrometer	Jasco J-815 (Eaton, USA)
electrophoresis (horizontal)	Biometra Compact XS/S (Göttingen, Germany)
electrophoresis (vertical)	Biometra Compact M (Göttingen, Germany) Biometra Minigel-Twin (Göttingen, Germany)
FPLC	ÄKTA purifier (GE Healthcare, Freiburg, Germany)
GC/MS	GC-MS-QP2010 Ultra (Shimadzu, Duisburg, Germany)
HPLC	VWR-Hitachi LaChrom Elite (VWR, Darmstadt, Germany)
ITC	MicroCal iTC200 (Malvern, Worcestershire, UK)
plate-reader	SpectraMax M5 (Molecular Devices, Biberach, Germany)
NMR-spectrometer	Varian Unity 400 (Agilent, Böblingen, Germany) Varian VNMRs 600 (Agilent, Böblingen, Germany)
photospectrometer	Eppendorf Biophotometer Plus (Hamburg, Germany) JASCO V-560 (Eaton, USA) Colibri Microvolume Spectrometer (Biozym, Hess. Oldendorf, Germany)
centrifuges	Eppendorf 5424 (Hamburg, Germany) Hettich Mikro 120 (Kirchlengern, Germany) Beckman Avanti J-E, Beckman Allegra X-30R (Krefeld, Germany)
centrifuge rotors	Beckman JA-10, JA-16.250, JS-4.3 (Krefeld, Germany)

3.1.8 Software

All mathematical and statistical computations and graphics were done with the R software (versions 3.1.X, <http://cran.r-project.org/>) [41]. Visualizations of macromolecules were arranged using the PyMol Molecular Graphics System, version 1.7.0.0 (Schrödinger, New York, USA). Physicochemical calculations and calculations of different molecular descriptors were performed using Marvin Beans 15.4.13.0 (ChemAxon, Budapest, Hungary) and Molecular Operating Environment 2008.10 (Chemical Computing Group, Montreal, Canada). Special software used for X-ray crystal structure solution is discussed separately in the corresponding section (3.5).

3.2 Molecular Biology

Basic molecular biology methods like polymerase chain reaction (PCR), DNA restriction/ligation, DNA gel electrophoresis, preparation of competent cells and

transformation were performed based on the protocols summarized by Sambrook and Russell [47]. Plasmid DNA was isolated using the QIAprep® Spin Miniprep Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. In vitro site-directed mutagenesis was set-up according to the protocol of the QuikChange™ Site-Directed Mutagenesis kit [2] offered by Agilent Technologies (Santa Clara, USA). Nucleotide fragments obtained by PCR, restriction/ligation procedures or excision from electrophoresis gels were purified and concentrated using the Nucleospin Gel and PCR Clean-up kit provided by Machery-Nagel (Düren, Germany) according to the instructions provided by the manufacturer.

### 3.2.1 Golden Gate Cloning

The Golden Gate cloning procedure is a one-pot method, meaning the restriction digestion and ligation are carried out in the same reaction vessel at the same time [27, 15]. Consequently PCR-fragments, destination vector, restriction endonuclease and ligase are added together in this reaction. The methodology employs type II restriction enzymes, which together with proper design of the fragments allow for a ligation product lacking the original restriction sites. For digestion/ligation reactions of fragments containing BpiI sites, 20 fmol of each fragment or vector, together with 5 U of BpiI and 5 U of T4 ligase were combined in a total volume of 15 µl 1× ligase buffer. For fragments to be cloned via BsaI sites, BpiI in the above reaction was substituted by 5 U BsaI. The reaction mixture was placed in a thermocycler and incubated at 37 °C for 2 min and 16 °C for 5 min. These two first steps were repeated 50 times over. Finally, the temperature was raised to 50 °C (5 min) and 80 °C (10 min) to inactivate the enzymes.

### 3.2.2 Subcloning of genes

All subcloning procedures were performed according to section 3.2 and specifically subsection 3.2.1. Specific steps for the subcloning of any genes discussed can be found in the appendix (p.38). The *pfomt* gene was subcloned from the pQE-30 vector kindly provided by Thomas Vogt (Leibniz-Institute of Plant Biochemistry (IPB), Halle, Germany) into the pET-28a(+) vector. The *somt-2* gene was subcloned from the pQE-30 vector kindly provided by Martin Dippe (IPB, Halle, Germany) into the pET-28-MC vector.

### 3.2.3 Transformation of electrocompetent *Agrobacterium tumefaciens* cells

A 50 µl aliquot of electrocompetent *A. tumefaciens* cells was thawed on ice. (50 to 100) ng of plasmid were added, the solution was mixed gently and transferred to a pre-cooled electroporation cuvette. After pulsing (2.5 kV, 200 Ω) 1 ml of lysogeny broth (LB)-medium was added, the mixture transferred to a 1.5 ml tube and incubated for (3 to 4) hours at 28 °C. The culture was centrifuged ( $10\,000 \times g$ , 1 min) and 900 µl supernatant were discarded. The pellet was resuspended in the remaining liquid, plated onto LB-agar plates supplemented with 40 µg/ml rifampicin and 50 µg/ml carbencillin and incubated at 28 °C for (2 to 3) days.

## 3.3 Treatment of plant material

### 3.3.1 Infiltration of *Nicotiana benthamiana*

Before infiltration *N. benthamiana* plants were pruned, such that only leaves to be infiltrated remained with the plant. 5 ml cultures of transformed *A. tumefaciens* in LB-medium (with 40 µg/ml rifampicin and 50 µg/ml carbencillin) were grown over night at 28 °C and 220 rpm.  $OD^{600}$  of the culture was measured and adjusted to 0.2 by dilution with infiltration buffer (10 mM MES/NaOH, 10 mM  $MgSO_4$  pH 5.5). When multiple *A. tumefaciens* transformed with different constructs/plasmids were used for infiltration, the cultures were mixed and diluted using infiltration buffer, such that  $OD^{600}$  of each culture in the mix was 0.2. The solution was infiltrated into the abaxial side of *N. benthamiana* leaves using a plastic syringe. The leaf material was harvested after 7 days.

### 3.3.2 Plant material harvest

Infiltrated/Infected areas of *N. benthamiana* leaf material were cut out and grouped by plant number, leaf position (top/bottom) and leaf side (right/left). The grouped clippings were weighed, frozen in liquid nitrogen, ground to a powder, freeze-dried and stored at -80 °C.

### 3.3.3 Extraction of flavonoids from *N. benthamiana* leaves

Two tips of a small spatula of freeze-dried material ( $\approx 6$  mg), were weighed exactly and extracted with 500 µl 75 % aqueous methanol containing 1 mM ascorbic acid, 0.2 % formic acid and 0.1 mM flavone (internal standard). Therefore the suspension was vortexed for 30 s, rotated on an orbital shaker for 10 min and vortexed again for

30 s. The suspension was centrifuged ( $20\,000 \times g$ ,  $4\,^{\circ}\text{C}$ , 10 min) and the supernatant transferrerd to a new tube, to remove the insoluble plant material. The supernatant was centrifuged again ( $20\,000 \times g$ ,  $4\,^{\circ}\text{C}$ , 10 min) and the resulting supernatant was transferred to a HPLC-vial and stored at  $-20\,^{\circ}\text{C}$  until analysis.

### 3.4 Protein biochemistry

Stock solutions of antibiotics, IPTG or sugars were prepared according to the pET System Manual by Novagen [38], unless otherwise noted.

#### 3.4.1 Determination of protein concentration

Protein concentrations were estimated using the absorption of protein solutions at 280 nm, which is mainly dependent on the amino acid composition of the protein studied [19]. Extinction coefficients of proteins were calculated from the amino acid sequence using the ExpPASy servers’s ProtParam tool [18].

Table 3.6.: Calculated extinction coefficients of proteins used in this work.

protein/enzyme	$\epsilon_{280\text{nm}}^{1\text{ g/l}}$ in $\text{ml mg}^{-1} \text{ cm}^{-1}$
PFOMT (reduced)	0.714
PFOMT Y51K N202W (reduced)	0.852
SOMT-2 (oxidized)	1.263
SOMT-2 (reduced)	1.247
COMT	

#### 3.4.2 Protein production test (expression test)

The heterologous production of proteins in *E. coli* was assessed in a small scale protein production test, henceforth called expression test. Single colonies of *E. coli* transformed with the constructs to be studied were used to inoculate a 2 ml starter culture in LB-medium containing the appropriate antibiotics. The working concentrations of antiobiotics used was as follows: 200  $\mu\text{g/ml}$  ampicillin, 150  $\mu\text{g/ml}$  kanamycin, 50  $\mu\text{g/ml}$  chloramphenicol, 20  $\mu\text{g/ml}$  tetracycline.

The starter culture was allowed to grow at  $37\,^{\circ}\text{C}$  and 200 rpm over night. A 5 ml sampling culture of the medium to be studied containing the appropriate antibiotics was prepared. The media tested included LB, terrific broth (TB) and auto-induction media like ZYP-5052. The sampling culture was inoculated to an  $\text{OD}^{600}$  of 0.075 using the starter culture and incubated at different temperatures and 200 rpm in

a shaking incubator. 1 mM isopropyl-D-thiogalactopyranosid (IPTG) was added when the  $OD^{600}$  reached 0.6-0.8, if appropriate for the studied construct. 1 ml samples were removed after different times of incubation (e.g. 4, 8, 12 hours), subfractionated (3.4.3) and analyzed via SDS-polyacrylamide gel electrophoresis (PAGE) (3.4.6).

Exact specifications of growth conditions (e.g. temperature, time, constructs) are discussed in the individual sections.

### 3.4.3 Protein subfractionation

The protein subfractionation procedure described herein was adapted from the protocol described in the pET Manual [38]. Overall 5 protein subfractions can be obtained, including *total cell protein*, *culture supernatant (medium) protein*, *periplasmic protein*, *soluble cytoplasmic protein* and *insoluble protein*.

The  $OD^{600}$  of the culture sample was measured and the cells harvested by centrifugation at  $10\,000 \times g$ ,  $4^\circ\text{C}$  for 5 minutes. The protein in the supernatant medium was concentrated by precipitation with trichloro acetic acid (TCA) (3.4.4) for SDS-PAGE analysis. The periplasmic protein was prepared (3.4.5) and also concentrated by TCA precipitation for SDS-PAGE. Cells were lysed by resuspending the cell pellet in  $(OD^{600} \times V \times 50) \mu\text{l}$  of bacterial protein extraction reagent (B-PER) and vortexing vigorously for 30 s. The suspension was incubated at room temperature (RT) for 30 min to assure complete lysis. To separate insoluble protein and cell debris from the soluble cytosolic protein, the suspension was centrifuged at  $10\,000 \times g$  and  $4^\circ\text{C}$  for 10 min. Soluble cytoplasmic protein was contained in the supernatant, whereas insoluble protein remained in the pellet. For SDS-PAGE analysis of the insoluble protein, the pellet was resuspended in the same volume of B-PER. To obtain only the total cell protein fraction, the preparation of periplasmic and soluble cytosolic protein was omitted. Sample volumes of  $10 \mu\text{l}$  of each fraction were used for SDS-PAGE analysis.

### 3.4.4 Protein sample concentration by TCA precipitation

Diluted protein samples were concentrated by TCA precipitation in microcentrifuge tubes. Therefore 0.1 volume (V) of 100 % (w/v) TCA in water was added to the clarified sample, which was then vortexed for 15 s and placed on ice for a minimum of 15 min. The sample was centrifuged at  $14\,000 \times g$ ,  $4^\circ\text{C}$  for 15 min. The supernatant was discarded and the pellet was washed twice with 0.2 V ice-cold acetone. The acetone was removed and the pellet set to air-dry in an open tube. After drying, the protein pellet was resuspended in 0.1 V phosphate buffered saline (PBS) containing  $1 \times$  SDS-sample buffer by heating to  $85^\circ\text{C}$  and vigorous vortexing, to achieve a

1 10 × concentration. After resuspension the sample was analyzed by SDS-PAGE or  
2 stored at −20 °C until use.

### 3 3.4.5 Preparation of periplasmic protein

4 Target proteins may be directed to the periplasmic space by N-terminal signal  
5 sequences like *pelB* or *DsbA/C* [31]. The periplasma is, other than the cytosol, an  
6 oxidizing environment and often used for the production of proteins containing  
7 disulfide linkages. The preparation of periplasmic protein was accomplished by an  
8 osmotic shock protocol modified from Current Protocols in Molecular Biology [5].  
9 The cell pellet was resuspended in the same volume as the culture sample of 30 mM  
10 tris-HCl, 20 % (w/v) sucrose, pH 8 and 1 mM ethylenediaminetetraacetic acid (EDTA)  
11 was added. The suspension was stirred for 10 min at RT and the cells were collected  
12 by centrifugation at 10 000 × *g*, 4 °C for 10 min. The supernatant was discarded  
13 and the cell pellet was resuspended in the same volume of ice-cold 5 mM MgSO<sub>4</sub>.  
14 The suspension was stirred for 10 min on ice, while the periplasmic proteins were  
15 released into the solution. The cells were collected by centrifugation as before.  
16 Periplasmic proteins were contained in the supernatant.

### 17 3.4.6 Discontinuous SDS-polyacrylamide gel electrophoresis 18 (SDS-PAGE)

19 The analysis of samples via SDS-PAGE was realized via the discontinuous system  
20 first described by Laemmli, which allows separation of proteins based on their  
21 electrophoretic mobility, which in turn depends on their size [29].  
22 The SDS-PAGE procedure was carried out according to standard protocols described  
23 by Sambrook and Russell [47]. Very dilute and/or samples with high ionic strength  
24 were concentrated and/or desalted by the TCA precipitation procedure described in  
25 subsection 3.4.4. Generally a 10 % (acrylamide/bisacrylamide) running gel combined  
26 with a 4 % stacking gel was used. Reducing SDS-PAGE sample buffer was added to  
27 the protein sample to be analyzed, whereafter the sample was heated to 95 °C for  
28 5 min, to allow for total unfolding of the protein. After cooling to RT the samples  
29 were transferred into the gel pockets for analysis. The *PageRuler™ Prestained*  
30 *Protein Ladder* (Life Technologies GmbH, Darmstadt, Germany) was used as a  
31 molecular weight (MW) marker and run alongside every analysis as a reference.  
32 Gels were stained using a staining solution of 0.25 % Coomassie Brilliant Blue G-  
33 250 (w/v) in water:methanol:acetic acid (4:5:1) and destained by treatment with  
34 water:methanol:acetic acid (6:3:1).



### 3.4.7 Buffer change of protein samples

The buffer in protein samples was exchanged either by dialysis, or by centrifugal filter concentrators (Amicon® Ultra Centrifugal Filter; Merck, Darmstadt, Germany). Large volumes of highly concentrated protein solutions were preferably dialyzed. Respectively, very dilute samples were concentrated and rebuffed using centrifugal concentrators.

Dialysis was carried out at least twice against a minimum of 100 times the sample volume. Dialysis steps were carried out at RT for 2 hours, or over-night at 4 °C. Centrifugal concentrators were used according to the manufacturers instructions.

### 3.4.8 Production of recombinant protein

#### Heterologous production of PFOMT

PFOMT was produced as a N-terminally (His)<sub>6</sub>-tagged fusion protein. A 2 ml starter culture of LB containing 100 µg/ml kanamycin was inoculated with a single colony of *E. coli* BL21(DE3) transformed with pET28-pfomt and incubated at 37 °C, 220 rpm for 6 hours. The main culture (N-Z-amine, yeast extract, phosphate (ZYP-5052) containing 200 µg/ml kanamycin) was inoculated with the starter culture such that OD<sup>600</sup> was 0.05. The culture was incubated in a shaking incubator at 37 °C, 220 rpm over night (≈16 h). Due to the autoinducing nature of the ZYP-5052 medium, addition of IPTG was not necessary. Cells were harvested by centrifugation at 10 000 × g, 4 °C for 10 min and the supernatant discarded. The pellet was resuspended in 50 mM Tris/HCl, 500 mM NaCl, 2.5 mM imidazole, 10 % glycerol pH 7 using a volume of ≈10 ml/g of cell pellet. The cells were lysed by sonication (70 % amplitude, 1 s on-off-cycle) for 30 seconds, which was repeated twice. The crude lysate was clarified by centrifugation at 15 000 × g, 4 °C for 15 minutes followed by filtration through a 0.45 µm filter. Consequently, the His-tagged PFOMT was purified by immobilized metal affinity chromatography (IMAC) (3.4.10). The eluted PFOMT protein was dialyzed (3.4.7) against 25 mM HEPES, 100 mM NaCl, 5 % glycerol pH 7 and stored at -20 °C until use.

#### Heterologous production of SOMT-2

SOMT-2 was produced as a fusion protein with an N-terminal His-tag. A starter LB-culture (≈ 2 ml) containing 100 µg/ml kanamycin was inoculated with a single colony of *E. coli* BL21(DE3) transformed with pET28MC-somt and incubated at 37 °C, 220 rpm for 6 hours. The starter culture was used to inoculate the main culture (LB-medium containing 100 µg/ml kanamycin), such that OD<sup>600</sup> ≈ 0.05. The culture was incubated at 37 °C, 220 rpm in a shaking incubator until OD<sup>600</sup>

BWEIGEL: Überprüfen!



1  $\approx 0.6$ . Expression was induced by addition of 1 mM IPTG. Incubation continued at  
 2 37 °C, 220 rpm for 6 hours. Cells were harvested by centrifugation ( $10\,000 \times g$ , 4 °C,  
 3 10 min) and used, or stored at -20 °C until use. SOMT-2 was produced in inclusion  
 4 bodies (IBs), which were prepared as laid out in subsection 3.4.9.

#### 5 3.4.9 Preparation of inclusion bodies (IBs)

6 Often, when recombinant protein is produced in high levels in *E. coli* it is accumu-  
 7 lated in so-called inclusion bodies (IBs) [45]. The accumulating IBs consist mainly  
 8 of the overproduced target protein, which is inherently quite pure already. IBs can  
 9 be selectively recovered from *E. coli* cell lysates and can consequently be refolded.  
 10 IBs were prepared according to a modified protocol by Palmer [39].  
 11 The cells were resuspended in 5 ml/g<sub>cells</sub> IB lysis buffer (100 mM Tris/HCl, 1 mM  
 12 EDTA pH 7), 0.5 mM phenylmethylsulfonylfluoride (PMSF) was added as protease  
 13 inhibitor. The solution was homogenized using a tissue grinder homogenizer (Ultra  
 14 Turrax®; IKA®-Werke GmbH & Co. KG, Staufen, Germany). 200 µg/ml lysozyme  
 15 was added to aid in the breakage of cells and the cells were lysed by sonicating  
 16 thrice at 70 % amplitude (1 s on-off-cycle) for 30 seconds. DNase I (10 µg/ml) was  
 17 added and the solution was incubated on ice for 10 min. The lysate was clarified by  
 18 centrifuging for 1 h at  $20\,000 \times g$ , 4 °C. The supernatant was discarded and the pellet  
 19 was resuspended in 5 ml/g<sub>cells</sub> IB wash buffer I (20 mM EDTA, 500 mM NaCl, 2 %  
 20 (w/v) Triton X-100 pH), followed by thorough homogenization. The solution was  
 21 centrifuged (30 min at  $20\,000 \times g$ , 4 °C), the supernatant discarded and the pellet  
 22 was washed twice more. To remove detergent, the pellet was washed twice again  
 23 with IB washing buffer II (20 mM EDTA, 100 mM Tris/HCl pH 7). The IBs were  
 24 resuspended in IB solubilization buffer (100 mM Tris/HCl, 5 mM DTT, 6 M GdmCl  
 25 pH 7), such that the protein concentration was about 25 mg/ml and stored at -20 °C  
 26 until use.

#### 27 3.4.10 Purification of His-tagged proteins using immobilized 28 metal affinity chromatography (IMAC)

29 N- or C-terminal oligo-histidine tags (His-tags) are a common tool to ease purifica-  
 30 tion of recombinantly produced proteins. The free electron pairs of the imidazol  
 31 nitrogens of histidines can complex divalent cations such as  $Mg^{2+}$  or  $Ni^{2+}$ , which  
 32 are usually immobilized on a matrix of nitrilo triacetic acid (NTA)-derivatives. The  
 33 affinity of the His-tag is correlated with its length and tagged proteins can simply  
 34 be eluted by increasing the concentration of competing molecules (e.g. imidazole).  
 35 His-tagged protein was purified by fast protein liquid chromatography (FPLC) via  
 36  $Ni^{2+}$ - (HisTrap FF crude) or  $Co^{2+}$ -NTA (HiTrap Talon FF crude) columns, obtained

from GE Healthcare (Freiburg, Germany), following modified suppliers instructions. First the column was equilibrated with 5 column volumes (CV) of binding buffer (50 mM Tris/HCl, 500 mM NaCl, 10 % glycerol, 2.5 mM imidazole pH 7). The sample (generally clarified lysate) was applied to the column using a flow of 0.75 ml/min. Unbound protein was removed by washing with 3 CV binding buffer. Unspecifically bound proteins were washed away by increasing the amount of elution buffer (50 mM Tris/HCl, 500 mM NaCl, 10 % glycerol, 250 mM imidazole pH 7) to 10 % (constant for 3 to 5 CV). Highly enriched and purified target protein was eluted with 6 to 10 CV of 100 % elution buffer.

3.4.11 Refolding of SOMT-2 on a micro scale using design of experiments (DoE)

Design of experiments (DoE) and FFD have been successfully used to optimize the refolding conditions of several proteins [55, 3, 6]. Thus, an approach using FFD was used to find optimal refolding conditions for SOMT-2. Factors studied were pH (buffer), arginine, glycerol, divalent cations, ionic strength, redox system, cyclodextrin and co-factor addition. The experimental matrix was constructed using the FrF2 package (<http://cran.r-project.org/web/packages/FrF2/index.html>) in the R software.

Table 3.7.: Factors used in the construction of the FFD.

factor	symbol	setting		unit
		-1	+1	
pH	A	5.5	9.5	-
arginine	B	0	0.5	M
glycerol	C	0	10	% (v/v)
divalent cations <sup>1</sup>	D	no	yes	-
ionic strength <sup>2</sup>	E	low	high	-
redox state <sup>3</sup>	F	reducing	redox-shuffling	-
α-cyclodextrin	G	0	30	mM
SAH	H	0	0.5	mM

<sup>1</sup>no: 1 mM EDTA; yes: 2 mM CaCl<sub>2</sub>, MgCl<sub>2</sub>  
<sup>2</sup>low: 10 mM NaCl, 0.5 mM KCl; high: 250 mM NaCl, 10 mM KCl  
<sup>3</sup>reducing: 5 mM DTT; redox-shuffling: 1 mM glutathione (GSH), 0.2 mM glutathione disulfide (GSSG)

**Table 3.8.:** Experimental design matrix for the FFD.

Experiment	A	B	C	D	E	F	G	H
1	+	+	+	-	-	-	-	+
2	-	-	-	-	-	-	-	-
3	+	-	+	+	-	+	+	-
4	-	+	+	-	+	+	+	-
5	+	+	-	-	+	+	-	-
6	-	+	-	+	+	-	+	+
7	+	+	-	+	-	-	+	-
8	-	-	+	-	+	-	+	+
9	+	-	+	+	+	-	-	-
10	-	-	-	-	-	+	+	+
11	+	-	-	+	+	+	-	+
12	-	+	+	+	-	+	-	+

1 The buffers were mixed from stock solutions and prepared in 1.5 ml microcen-  
2 trifugetubes immediately prior to the experiment. 50 µl of solubilized SOMT-2  
3 (1 mg/ml) in IB solubilization buffer was added to each buffer followed by a short  
4 vortex boost for rapid mixing. The final protein concentration in the refolding  
5 reaction was 50 µg/ml, whereas the remaining GdmCl concentration was ≈286 mM.  
6 The refolding reactions were incubated at RT for 1 hour, followed by an over  
7 night incubation at 4 °C. After incubation the refolding reactions were centrifuged  
8 (10 000 × g, 4 °C, 10 min) to separate insoluble and soluble protein fractions. The  
9 supernatant was transferred to a new tube, whereas the pellet was washed twice  
10 with 200 µl acetone and once with 400 µl methanol/acetone (1:1). The pellet was  
11 resuspended in 100 µl PBS with 20 µl SDS-PAGE sample buffer and 10 µl were used  
12 for SDS-PAGE analysis.  
13 100 µl of the supernatant were concentrated using TCA precipitation (3.4.4) and  
14 analyzed by SDS-PAGE. The remaining supernatant was rebuffed into 50 mM  
15 2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol (BisTris) pH 7.5  
16 using Amicon® Ultra 0.5 ml centrifugal filters (Merck, Darmstadt, Germany)  
17 according to the manufacturers instructions. The pre-weighed collection tubes  
18 were re-weighed after recovery and the volume of recovered liquid calculated  
19 ( $\rho \approx 1 \text{ g/cm}^3$ ). The sample was filled up to 100 µl using 50 mM BisTris pH 7.5 and  
20 the protein concentration was assessed using the Roti®-Quant protein quantifi-  
21 cation solution (Carl Roth, Karlsruhe, Germany) according to the manufacturers  
22 description. 50 µl of each refolded sample was used for an activity test using  
23 naringenin as substrate (3.6.3). The reactions were incubated over night and  
24 stopped by the extraction method. However, before the actual extraction 1 µl of

anthracene-9-carboxylic acid (AC-9) was added as internal standard. The samples were analyzed by high-performance liquid chromatography (HPLC).

#### Assessment of refolding performance

The performance of each buffer on the refolding of SOMT-2 was examined by comparing the SDS-PAGE results, as well as the amount of soluble protein and the conversion of substrate. Main effects were analyzed qualitatively using main effects plots [7].

#### Upscaling of refolding reactions

Refolding reactions were scaled up to 50 ml. Therefore 2.5 ml solubilized SOMT-2 (1 mg/ml) were added over 10 minutes to 50 ml of refolding buffer while stirring at RT. The refolding reaction was allowed to complete over night at 4 °C.

#### 3.4.12 Enzymatic production of SAM and SAE

*S*-adenosyl-L-methionine (SAM) and *S*-adenosyl-L-ethionine (SAE) were prepared according to the method described by Dippe, et. al [13].

Preparative reactions (20 ml) were performed in 0.1 M Tris/HCl, 20 mM MgCl<sub>2</sub>, 200 mM KCl pH 8.0 and contained 7.5 mM adenosine triphosphate (ATP), 10 mM D,L-methionine or D,L-ethionine, for the production of SAM or SAE respectively, and 0.2 U *S*-adenosylmethionine synthase (SAMS) variant I317V. The reaction was stopped by lowering the pH to 4 using 10 M acetic acid after 18 h of incubation at 30 °C, 60 rpm. After 10 min incubation on ice the solution was centrifuged (15 000 × *g*, 10 min) to remove insoluble matter. The supernatant was transferred to a round bottom flask, frozen in liquid nitrogen and lyophilized.

Crude products were extracted from the pellet using 73 % ethanol and purified using ion exchange chromatography (IEX). IEX was performed on a sulfopropyl sepharose matrix (25 ml) via isocratic elution (500 mM HCl). Before injection, the crude extract was acidified to 0.5 M HCl using concentrated hydrochloric acid. After elution, the product containing fractions were dried via lyophilization.

The amount of product was determined by UV/VIS-spectroscopy at 260 nm using the published extinction coefficient of SAM ( $\epsilon_0 = 15\,400\text{ M}^{-1}\text{ cm}^{-1}$ ) after resuspension in water [49].

### 3.5 Crystallographic Procedures

### 3.5.1 Crystallization of proteins

Commercially available crystallization screens were used to find initial crystallization conditions. The tested screens included kits available from Hampton Research (Aliso Viejo, USA) and Jena Bioscience (Jena, Germany). Crystallization screens were processed in 96-well micro-titer plate (MTP)s, where each well possessed 4 subwells aligned in a 2×2 matrix. The subwells were divided into 3 shallow wells for sitting drop vapour diffusion experimental setups and a fourth subwell, which was deep enough to act as buffer reservoir. This way the performance of each crystallization buffer could be assessed using three different protein solutions with varying concentrations, effectors etc. A pipetting robot (Cartesian Microsys, Zinsser-Analystik; Frankfurt, Germany) was used to mix 200 nl of each, protein and buffer solution, for a final volume of 400 nl. The crystallization preparations were incubated at 16 °C and the progress of the experiment was documented by an automated imaging-system (Desktop Minstrel UV, Rigaku Europe, Kent, UK). Furthermore, fine screens (e.g. for refinement of crystallization conditions) were set up by hand in 24-well MTPs using the hanging drop vapour diffusion method.

#### PFOMT

PFOMT protein was concentrated to (6 to 8) mg/ml and rebuffed to 10 mM Tris/HCl pH 7.5 using Amicon® Ultracel centrifugal concentrators (10 kDa MWCO). The concentrated protein solution was centrifuged at  $14\,000 \times g$ , 4 °C for 10 min to remove any insoluble material or aggregates. Crystallization screens were set up as described above. *apo*-PFOMT was crystallized using the following conditions – 2 M  $(\text{NH}_4)_2\text{SO}_4$ , 20 %glycerol. The protein solution contained 0.25 mM SAE, 0.25 mM  $\text{MgCl}_2$ , 0.25 mM eriodictyol and 7.53 mg/ml (0.262 mM) PFOMT.

#### Crystallization of proteins using NADES

NADES have the potential to be excellent solvents for hydrophobic compounds such as flavonoids or cinnamic acids [10] and in addition they are able to stabilize and activate enzymes [20].

Four different model proteins (bovine trypsin, hen-egg white lysozyme, proteinase K and *Candida cylindrica* lipase B) were used to assess the capability of NADES for protein crystallization. PCH was tested in a full factorial grid layout using PCH concentrations of (20, 30, 40 and 50) % combined with buffers of different pH. The buffers included 0.1 M sodium acetate pH (4.5 and 5.5), 0.1 M sodium citrate pH 6.5, 0.1 M 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES)/NaOH pH (7 and 7.5) and 0.1 M Tris/HCl pH 8.5. Thus, the full

BWEIGEL: To introduction

factorial design had a size of  $4 \times 6 = 24$  different conditions. Protein solutions were prepared from lyophilized protein and were as follows: 90 mg/ml trypsin in 10 mg/ml benzamidine, 3 mM  $\text{CaCl}_2$ ; 75 mg/ml lysozyme in 0.1 M sodium acetate pH 4.6; 24 mg/ml proteinase K in 25 mM Tris/HCl pH 7.5 and 6 mg/ml lipase B in water. For crystallization 2  $\mu\text{l}$  enzyme solution and 1  $\mu\text{l}$  reservoir buffer were mixed and set up in a hanging drop experiment on a 24-well MTP. The experiments were set up at 4 °C.

### 3.5.2 Data collection and processing

Crystallographic data were collected at the beamline of the group of Professor Stubbs (MLU, Halle, Germany). The beamline was equipped with a rotating anode X-ray source MicroMax007 (Rigaku/MSK, Tokyo, Japan), which had a maximum power of 0.8 kW (40 kV, 20 mA) and supplied monochromatic  $\text{Cu-K}\alpha$ -radiation with a wavelength of 1.5418 Å. Diffraction patterns were detected with a Saturn 944+ detector (CCD++, Rigaku/MSK, Tokyo, Japan). Indexing and integration of the reflexes via Fourier transformation (FT) was accomplished using XDS [25, 24, 26] or MOSFLM [40]. *Scala* [16], which is integrated in the Collaborative Computational Project No. 4 (CCP4)-Suite, was used for scaling of the intensities.

### 3.5.3 Structure solution

For the determination of the electron density  $\rho(\mathbf{r})$ , where  $\mathbf{r}$  is the positional vector, from the diffraction images by FT two terms are necessary as coefficients; the structure factor amplitudes,  $F_{\text{obs}}(\mathbf{h})$  and the phase angles or phases,  $\alpha(\mathbf{h})$ , where  $\mathbf{h}$  is the reciprocal index vector. The structure factor amplitudes can be directly determined from the measured and corrected diffraction intensities of each spot. However, the phase information is lost during the detection of the diffracted photons and there is no direct way to determine the phases. This constitutes the so-called phase problem. Thus, additional phasing experiments are necessary in order to obtain the phases. A variety of phasing experiments are available, which include marker atom substructure methods, density modification and molecular replacement (MR) techniques [46]. Phases of the structures herein were exclusively determined by MR [43, 44].

MR was performed using the software Phaser [32, 33], which is included in the CCP4-Suite [56]. A previously published PFOMT structure (PDB-code: 3C3Y [28]) was used as a template during MR procedure for the PFOMT structure solution. For the MR of the lysozyme structure the PDB-entry 4NHI was used.

BWEIGEL: Lysozym struktur



### 3.5.4 Model building, refinement and validation

Macromolecular model building and manipulation, as well as real space refinement and Ramachandran idealization were performed using the Crystallographic Object-Oriented Toolkit (*Coot*) software [14]. Structure refinement was done using the software REFMAC5 [36, 53] as part of the CCP4-suite or the Phyton-based Hierarchical Environment for Integrated Xtallography (PHENIX) [1]. Validation of the structures was carried out using the web service MolProbity (<http://molprobity.biochem.duke.edu/>) [8]. Structure visualization and the preparation of figures was performed using PyMOL (Schrödinger, New York, USA).

### 3.5.5 *In silico* substrate docking

*In silico* molecular docking studies were performed using the AutoDock Vina 1.1.2 or AutoDock 4.2.6 software in combination with the AutoDockTools-Suite (<http://autodock.scripps.edu/>) [21, 35, 52]. Substrates were docked into the PFOMT structure with the PDB-code 3C3Y. The grid box, which determines the search space, was manually assigned to center at 1.581, 5.196 and 25.718 (x, y, z) and had size of (22, 20 and 25) Å (x, y, z). The exhaustiveness of the global search for AutoDock Vina was set to 25, whereas the rest of the input parameters were kept at their defaults.

## 3.6 Analytics

### 3.6.1 Recording of growth curves

Starter cultures ( $\approx 2$  ml) of the transformed *E. coli* cells were prepared in the medium to be studied, containing the appropriate antibiotics. The cultures were incubated at 37 °C, 200 rpm over night and harvested by centrifugation ( $5000 \times g$ , 4 °C, 5 min). The pellet was resuspended in 15 ml PBS and the suspension centrifuged ( $5000 \times g$ , 4 °C, 5 min). The supernatant was discarded and the washing step repeated once more. The washed pellet was resuspended in 2 ml of the medium to be studied with the appropriate antibiotics and the OD<sup>600</sup> was measured. Three independent 50 ml cultures of the medium containing the appropriate antibiotics were inoculated such that OD<sup>600</sup>  $\approx$  0.05 using the washed cell suspension. The cultures were incubated at the conditions to be studied and sampled at appropriate intervals of time ( $\approx 1$  h). One ml samples were kept on ice until all samples were acquired. 100  $\mu$ l aliquots of the samples were transferred into a clear MTP and the OD<sup>600</sup> was measured. Green fluorescent protein (GFP) fluorescence was measured accordingly, but the

<sup>1</sup> MTP used was opaque. Excitation ( $\lambda^{\text{ex}}$ ) and emission ( $\lambda^{\text{em}}$ ) wavelengths were (470  
<sup>2</sup> and 510) nm respectively.

### <sup>3</sup> 3.6.2 *In vitro* determination of glucose

<sup>4</sup> The glucose concentration in clarified, aqueous samples was determined by a mod-  
<sup>5</sup> ified version of the glucose assay kit procedure provided by Sigma-Aldrich [50].  
<sup>6</sup> Glucose oxidase (GOD) oxidizes D-glucose to gluconic acid, whereby hydrogen  
<sup>7</sup> peroxide is produced. The hydrogen peroxide can be detected and quantified by  
<sup>8</sup> horseradish peroxidase (HRP), which reduces the produced  $\text{H}_2\text{O}_2$  and thereby oxi-  
<sup>9</sup> dizes its chromogenic substrate *o*-dianisidine via consecutive one-electron transfers.  
<sup>10</sup> The oxidized diimine form of *o*-dianisidine can then be measured photospectro-  
<sup>11</sup> metrically [9].


<sup>12</sup> The methodology employs a coupled photospectrometric assay using GOD and HRP  
<sup>13</sup> with *o*-dianisidine as reporter substrate. The assay was prepared in MTP-format.  
<sup>14</sup> A reaction solution containing 12.5 U/ml GOD, 2.5 U/ml HRP and 0.125 mg/ml *o*-  
<sup>15</sup> dianisidine dihydrochloride in 50 mM sodium acetate pH 5.1 was prepared.  
<sup>16</sup> Sample solutions from culture supernatants were typically diluted in 9 volumes of  
<sup>17</sup> water. The reaction was started, by adding 50  $\mu\text{l}$  reaction solution to 25  $\mu\text{l}$  of sample  
<sup>18</sup> and was incubated at 37 °C and 200 rpm for 30 min in a shaking incubator. 50  $\mu\text{l}$   
<sup>19</sup> 6 M sulfuric acid was added to stop the reaction and achieve maximum color devel-  
<sup>20</sup> opment (full oxidation of any *o*-dianisidine charge transfer complexes) (Figure 3.1).  
<sup>21</sup> The developed pink color was measured at 540 nm in a MTP-reader. A calibration  
<sup>22</sup> curve of a standard D-glucose solutions (0 to 100  $\mu\text{g}/\text{ml}$ ), that was always part of  
<sup>23</sup> the experiments, was used to quantify the sample measurements.

### <sup>24</sup> 3.6.3 *In vitro* O-methyl transferase (O-MT) assay

<sup>25</sup> *O*-methyl transferase (O-MT) assays were conducted in a total volume of (50  
<sup>26</sup> to 100)  $\mu\text{l}$ . The standard assay buffer was 100 mM Tris/HCl, 2.5  $\mu\text{M}$  GSH pH 7.5.  
<sup>27</sup> 1 mM  $\text{MgCl}_2$ , which was otherwise omitted, was added for reactions using cation  
<sup>28</sup> dependent O-MTs (e.g. PFOMT). Reactions contained 0.5 mM alkyl donor (e.g. (*S,S*)-  
<sup>29</sup> SAM) and 0.4 mM flavonoid or cinnamic acid substrate. Enzymatic reactions were  
<sup>30</sup> started by addition of enzyme (usually 0.2 mg/ml) and incubated at 30 °C.  
<sup>31</sup> Reactions were stopped by addition of 500  $\mu\text{l}$  ethyl acetate containing 2 % formic acid  
<sup>32</sup> and vortexed for 15 s to extract the hydrophobic phenylpropanoids and flavonoids.  
<sup>33</sup> After centrifugation ( $10\,000 \times g$ , 4 °C, 10 min) the organic phase was transferred  
<sup>34</sup> into a new tube. The reaction was extracted once more with 500  $\mu\text{l}$  ethyl acetate,  
<sup>35</sup> 0.2 % formic acid and the pooled organic phases were evaporated using a vacuum  
<sup>36</sup> concentrator (Concentrator 5301; eppendorf, Hamburg, Germany). The residue was

BWEIGEL: nochmal auseinanderk-  
 lamüßern wegen den konzentrationen  
 und eingesetzten enzyymmengen...





**Figure 3.1.:** Oxidation of the reporter substrate *o*-dianisidine. Consecutive one-electron transfers lead to the fully oxidized diimine form of *o*-dianisidine. The first electron transfer is believed to produce a charge transfer complex intermediate. [23, 9]

dissolved in methanol and centrifuged at  $10\,000 \times g$  for 10 min to remove insoluble matter. The supernatant was transferred into a HPLC vial and analyzed by HPLC (3.6.8).

When detection of hydrophobic (e.g. flavonoids) and hydrophilic compounds (e.g. SAM, SAH) was performed simultaneously reactions were stopped by addition of 0.3 volumes 10 % (w/v) TCA in 50 % acetonitrile. The mixture was vortexed for complete mixing and incubated on ice for at least 30 min. After centrifugation ( $10\,000 \times g$ , 4 °C, 10 min) the supernatant was transferred into HPLC-sample vials and analyzed (see 3.6.8).


#### Measurement of activity/pH profiles

Assays to measure activity over larger pH ranges were set up in 50 mM L-malic acid/MES/Tris (MMT)- (pH 4 to 9) or succinate/sodium phosphate/glycine (SSG)-buffer (pH 4 to 10) to keep the concentrations of buffer salts constant for each pH [37].

The protein of interest was first extensively dialyzed against the reaction buffer (e.g. MMT, SSG) at pH 7 with added EDTA (5 mM) and then against the same buffer without EDTA. Standard reaction conditions were 50 mM buffer, 0.4 mM alkyl acceptor (e.g. caffeic acid), 0.5 mM SAM, 2.5  $\mu$ M GSH and 0.2 mg/ml enzyme.  $\text{MgCl}_2$  was either omitted or added at 10 mM to assess influences of divalent cations. Assays were stopped as described in 3.6.3 and analyzed accordingly.

#### 3.6.4 Photospectrometric assay for the methylation of catecholic moieties

Catecholic moieties can form stable complexes in the presence of heavy metals such as copper or iron [48, 34]. Hence, caffeic acid can complex ferric ( $\text{Fe}^{3+}$ ) ions and form a colored complex with  $\lambda_{\text{max}} = 595 \text{ nm}$  [12]. Since the complex formation is specific for caffeic acid and methylated derivatives (i.e. ferulic and iso-ferulic acid) cannot complex  $\text{Fe}^{3+}$ , this can be used as a measure for methylation reactions. O-MT assays were prepared as before (3.6.3). However, the reactions were stopped by addition of 0.1 volumes 1 M Tris/HCl pH 8, immediately followed by 0.5 volumes catechol reagent (2 mM  $\text{FeCl}_3$  in 10 mM HCl). The complex formation reaction was allowed to equilibrate for 5 min at RT and the absorbance at 595 nm was measured.



**Figure 3.2.:** Calibration curves of different relative compositions of ferulic acid to caffeic acid, that were taken as described in 3.6.4. The total concentration was always 0.4 mM. At lower pH values around 4, the method seems to overestimate the concentration of caffeic acid. However, the slope of the curves stays the same.

### 3.6.5 Concentration of SOMT-2 using hydrophobic interaction chromatography (HIC)

After refolding using rapid dilution protein samples are very dilute and a concentration step is required. Refolded SOMT-2 was concentrated directly from the refolding buffer using hydrophobic interaction chromatography (HIC). The ammonium sulfate concentration of the protein sample was brought to 1 M using a 2 M  $(\text{NH}_4)_2\text{SO}_4$  solution and the pH was adjusted to 7 using 5 M NaOH. The sample was centrifuged ( $20\,000 \times g$ ,  $4^\circ\text{C}$ , 30 min) to remove insoluble material and the clarified supernatant was applied to a 1 ml HiTrap Phenyl FF (Low Sub) (GE Healthcare, Freiburg, Germany), which had been equilibrated with high salt buffer (1 M  $(\text{NH}_4)_2\text{SO}_4$ , 50 mM HEPES pH 7). The target protein was eluted using a stepwise gradient ((1, 0.8, 0.6, 0.4, 0.2 and 0) M  $(\text{NH}_4)_2\text{SO}_4$ , 50 mM HEPES pH 7; 5 CV each) to remove the ammonium sulfate. The column was washed using 20 % ethanol. Before SDS-PAGE analysis the eluted high salt fractions were desalted using TCA precipitation (3.4.4).

### 3.6.6 Analytical gel filtration

Analytical gel filtration was done using a Superdex 200 10/300 GL column (GE Healthcare, Freiburg, Germany) in combination with a FPLC system according to the manufacturers instructions. The column was equilibrated using an appropriate buffer (e.g. 0.1 M Tris/HCl pH 7.5) and 100  $\mu\text{l}$  of sufficiently concentrated ( $\geq 1\text{ mg/ml}$ ) protein sample were injected. The Gel Filtration Standard by Bio-Rad (München, Germany) was run separately to assess the size of the proteins in the analyzed sample.

### 3.6.7 Binding experiments using Isothermal Titration Calorimetry (ITC)

Isothermal Titration Calorimetry (ITC) can be used to directly characterize the thermodynamics of an observed process, be this a binding interaction or an enzymatic reaction [17].

ITC measurements to describe the interaction between PFOMT and its substrates/-effector were performed using a MicroCal iTC200 device (Malvern, Worcestershire, UK). PFOMT protein was extensively dialyzed against 50 mM MMT-buffer pH 7 prior to ITC experiments. The solution was subsequently centrifuged ( $14\,000 \times g$ ,  $4^\circ\text{C}$ , 10 min), to remove insoluble matter and aggregates. The dialysate was stored at  $4^\circ\text{C}$  and used to prepare substrate and effector solutions. Generally 50  $\mu\text{M}$  protein was provided in the ITC cell and the effectors/substrates to be titrated were loaded

1 into the syringe. The substance concentration in the syringe was ten times higher  
2 than the protein solution. Experiments were carried out at 20 °C unless otherwise  
3 stated. The stirring speed was set to 500 rpm. The injection volume was set to (2 to  
4 4) µl, amounting to a total of 10 to 19 injections.

### 5 3.6.8 High-performance liquid chromatography (HPLC) ana- 6 lytics

7 Due to their aromaticity, methanolic extracts of flavonoids exhibit two major  
8 absorption peaks in the UV/VIS region of the light spectrum in the range of (240 to  
9 400) nm [30]. However, even the more simple phenyl propanoids (e.g. cinnamic  
10 acids) show absorption of light in the UV/VIS-region.

11 Methanolic extracts of flavonoids and phenyl propanoids were analyzed by HPLC  
12 using a photo diode array (PDA)-detector, which was set to record in the range of  
13 (200 to 400) nm. HPLC runs were performed on a reverse-phase C-18 end-capped  
14 column (YMC-Pack ODS-A; YMC Europe, Dinslaken, Germany) with a pore size of  
15 120 Å. The mobile phase was aqueous acetonitrile supplemented with 0.2 % formic  
16 acid. The flow was kept constant at 0.8 ml/min. 10 µl *O*-MT enzyme assay extract  
17 (3.6.3) were injected and analyzed using an acetonitrile gradient starting with 5 %  
18 acetonitrile (4 min). The acetonitrile content was increased to 100 % in 21 min and  
19 was kept at 100 % for 5 min. Peaks were integrated from the 280 nm trace using the  
20 software provided by the manufacturer of the device.

### 21 3.6.9 liquid chromatography coupled mass-spectrometry 22 (LC/MS) measurements

# <sup>1</sup>4 **Evaluation of PFOMT towards** <sup>2</sup>**the acceptance of long-chain SAM** <sup>3</sup>**analogues**

## <sup>4</sup>4.1 **Introduction**

## <sup>5</sup>4.2 **Substrate binding studies using ITC**

## <sup>6</sup>4.3 **Determination of the structure of *apo*-PFOMT**

### <sup>7</sup>4.3.1 **PFOMT activity in deep eutectic solvents (DES) / Solubility- <sup>8</sup>enhancing effects of DES**

<sup>9</sup>vielleicht eigenes kapitel DES?

## <sup>10</sup>4.4 **Study of variants for long-chain alkylations**

### <sup>11</sup>4.4.1 **PFOMT-Paper (DIM)**

### <sup>12</sup>4.4.2 **Dockings???**

## <sup>13</sup>4.5 **Colclusion/Discussion**

## <sup>1</sup> 5 Enzymatic methylation of Non- <sup>2</sup> catechols

### <sup>3</sup> 5.1 Introduction

<sup>4</sup> Non-catechols in nature (biosynthesis, mode of action?), chemical methylation???

### <sup>5</sup> 5.2 SOMT-2

<sup>6</sup> 5.2.1 In vivo methylation studies using *N. benthamiana*

<sup>7</sup> 5.2.2 In vivo studies in *E. coli*

<sup>8</sup> 5.2.3 In vitro studies using recombinantly produced SOMT-2

### <sup>9</sup> 5.3 PFOMT

<sup>10</sup> 5.3.1 Acidity and Nucleophilicity of phenolic hydroxyl-groups

<sup>11</sup> 5.3.2 pH-Profiles of PFOMT-catalysis

<sup>12</sup> 5.3.3 Influence of  $Mg^{2+}$  on PFOMT activity

<sup>13</sup> 5.4 Consensus or Bioinformatic points-of-view  
<sup>14</sup> (COMT)???

<sup>15</sup> 5.5 Conclusion/Discussion

# **6 Development of an whole cell methyl transferase screening system**

## **6.1 Introduction**

## **6.2 Theoretical considerations / design of system**

## **6.3 Detectability of S-adenosyl-L-homocysteine (SAH)**

SAM

## **6.4 Usage of the *lsr*-promoter for true autoinduction**

## **6.5 Conclusion/Discussion**



## <sup>1</sup> **7 DES in protein crystallography**

### <sup>2</sup> **7.1 Introduction**

### <sup>3</sup> **7.2 Solubility enhancement of hydrophobic substances by addition of DES** <sup>4</sup>

### <sup>5</sup> **7.3 Enzymatic *O*-methylation in DES**

### <sup>6</sup> **7.4 DES as precipitants in protein crystallization**

### <sup>7</sup> **7.5 Conclusion/Discussion**

# 8 Acknowledgements

Quisque ullamcorper placerat ipsum. Cras nibh. Morbi vel justo vitae lacus tincidunt  
ultrices. Lorem ipsum dolor sit amet, consectetur adipiscing elit. In hac habitasse  
platea dictumst. Integer tempus convallis augue. Etiam facilisis. Nunc elementum  
fermentum wisi. Aenean placerat. Ut imperdiet, enim sed gravida sollicitudin,  
felis odio placerat quam, ac pulvinar elit purus eget enim. Nunc vitae tortor. Proin  
tempus nibh sit amet nisl. Vivamus quis tortor vitae risus porta vehicula.  
Fusce mauris. Vestibulum luctus nibh at lectus. Sed bibendum, nulla a faucibus  
semper, leo velit ultricies tellus, ac venenatis arcu wisi vel nisl. Vestibulum diam.  
Aliquam pellentesque, augue quis sagittis posuere, turpis lacus congue quam,  
in hendrerit risus eros eget felis. Maecenas eget erat in sapien mattis porttitor.  
Vestibulum porttitor. Nulla facilisi. Sed a turpis eu lacus commodo facilisis. Morbi  
fringilla, wisi in dignissim interdum, justo lectus sagittis dui, et vehicula libero dui  
cursus dui. Mauris tempor ligula sed lacus. Duis cursus enim ut augue. Cras ac  
magna. Cras nulla. Nulla egestas. Curabitur a leo. Quisque egestas wisi eget nunc.  
Nam feugiat lacus vel est. Curabitur consectetur.


1

2



# Appendix

## A Figures



**Figure A.1.:** Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem.

## **B** Tables

**Table B.1.:** Overview over the constructs produced for the present thesis. Each step during the production of the construct is given in the workflow steps column. Primers (*italic font*) or restriction sites used during each step are displayed in parenthesis.

construct name	description	entry constructs	destination	workflow steps (primers/cloning sites)
pBEW101	lsrA promoter pBEW102 with BamHI cloning site rhaP <sub>BAD</sub> promoter	pBEW102 pBEW4b	pBEW103	amplification ( <i>pRha1.fw/rv</i> ), cloning (BglII, BamHI)
pBEW102				
pBEW103				
pBEW104				
pBEW106	pICH413038-somt	pET28MC-somt	pICH413038	amplification ( <i>somt1/2/3/4</i> ), golden gate cloning (Bpil)
pBEW107		pICH51266, pBEW106, pICH41421	pICH75044	golden gate cloning (BsaI)
pBEW1a				
pBEW1b				
pBEW2a				
pBEW2b				
pBEW3a				
pBEW3b				
pBEW4a				
pBEW4b				
pET28-pfomt	<i>pfomt</i> gene in pET-28a(+), endogenous NdeI site removed	pQE30-pfomt	pET-28a(+)	mutagenesis ( <i>pfomt1.fw/rv</i> ), amplification ( <i>pfomt2.fw/rv</i> ), cloning (NdeI, EcoRI)
pET20-somt	N-terminal pelB-tag fusion for periplasmic expression		pET20-b(+)	
pET28-somt			pET28-a(+)	
pET28MC-somt	N-terminal Trx-tag fusion N-terminal GST-tag fusion added BglII site pUC19 derivative with lsrA promoter	pUC19 lsr-XX-DAS	pET-32a(+)	mutagenesis ( <i>pUC1.fw/rv</i> ) cloning (NdeI, BglII)
pET32-somt			pET-41a(+)	
pET41-somt			-	
pUC19*			pUC19*	
pUCB1				
pUCB1-sfGFP-DAS+4				

## <sup>1</sup> **C Affidavit**

<sup>2</sup> I hereby declare that this document has been written only by the undersigned and  
<sup>3</sup> without any assistance from third parties. Furthermore, I confirm that no sources  
<sup>4</sup> have been used in the preparation of this document other than those indicated in  
<sup>5</sup> the thesis itself.

<sup>6</sup> Date:....., Location:....., Signature:.....

## Bibliography

- [1] Paul D. Adams et al. “PHENIX: A comprehensive Python-based system for macromolecular structure solution”. en. In: *Acta Crystallographica Section D: Biological Crystallography* 66.2 (Feb. 2010), pp. 213–221.
- [2] Agilent Technologies. *QuikChange II Site-Directed Mutagenesis Kit: Instruction Manual*. 2011.
- [3] Neda Akbari et al. “Efficient refolding of recombinant lipase from *Escherichia coli* inclusion bodies by response surface methodology.” In: *Protein expression and purification* 70.2 (Apr. 2010), pp. 254–9.
- [4] Bernd Anselment et al. “Experimental optimization of protein refolding with a genetic algorithm”. In: *Protein Science* 19.11 (2010), pp. 2085–2095.
- [5] Frederick M Ausubel et al. “Current Protocols in Molecular Biology”. In: (2008), p. 23.
- [6] Isabelle Benoit et al. “Expression in *Escherichia coli*, refolding and crystallization of *Aspergillus niger* feruloyl esterase A using a serial factorial approach.” In: *Protein expression and purification* 55.1 (Sept. 2007), pp. 166–74.
- [7] George E. P. Box, J. Stuart Hunter, and William G. Hunter. *Statistics for Experimenters: Design, Innovation, and Discovery*. 2nd ed. New York: Wiley-Interscience, 2005, p. 633.
- [8] Vincent B Chen et al. “MolProbity: all-atom structure validation for macromolecular crystallography.” In: *Acta crystallographica. Section D, Biological crystallography* 66.Pt 1 (Jan. 2010), pp. 12–21.
- [9] Al Claiborne and Irwin Fridovich. “Chemical and Enzymatic Intermediates in the Peroxidation of o-Dianisidine by Horseradish Peroxidase. 1. Spectral Properties of the Products of Dianisidine Oxidation”. In: *Biochemistry* 18 (1979), pp. 2324–2329.
- [10] Yuntao Dai et al. “Natural deep eutectic solvents as new potential media for green technology.” In: *Analytica chimica acta* 766 (Mar. 2013), pp. 61–8.



- [11] Martin Dippe, Lars Dressler, and Renate Ulbrich-Hofmann. “Fe(III)-resorcyate as a spectrophotometric probe for phospholipid-cation interactions.” In: *Analytical biochemistry* 445 (Jan. 2014), pp. 54–9.
- [12] Martin Dippe et al. “Engineering of a Mg<sup>2+</sup>-dependent O-methyltransferase towards novel regiospecificity”. In: *manuscript submitted* (2015).
- [13] Martin Dippe et al. “Rationally engineered variants of S-adenosylmethionine (SAM) synthase: reduced product inhibition and synthesis of artificial co-factor homologues.” en. In: *Chemical communications (Cambridge, England)* 51.17 (Feb. 2015), pp. 3637–40.
- [14] P. Emsley et al. “Features and development of Coot”. In: *Acta Crystallographica Section D: Biological Crystallography* 66.4 (2010), pp. 486–501.
- [15] Carola Engler, Romy Kandzia, and Sylvestre Marillonnet. “A one pot, one step, precision cloning method with high throughput capability”. In: *PLoS ONE* 3.11 (Jan. 2008), e3647.
- [16] Philip Evans. “Scaling and assessment of data quality”. In: *Acta Crystallographica Section D: Biological Crystallography* 62.1 (Jan. 2006), pp. 72–82. arXiv: S0907444905036693 [doi : 10 . 1107 ].
- [17] Matthew W Freyer and Edwin a Lewis. “Isothermal titration calorimetry: experimental design, data analysis, and probing macromolecule/ligand binding and kinetic interactions.” In: *Methods in cell biology* 84.07 (Jan. 2008), pp. 79–113.
- [18] E. Gasteiger et al. “Protein Identification and Analysis Tools on the ExPASy Server”. In: *The Proteomics Protocols Handbook*. Ed. by John M. Walker. Humana Press, 2005, pp. 571–607.
- [19] S C Gill and P H von Hippel. “Calculation of protein extinction coefficients from amino acid sequence data.” In: *Analytical biochemistry* 182.2 (Nov. 1989), pp. 319–26.
- [20] Ze Lin Huang et al. “Deep eutectic solvents can be viable enzyme activators and stabilizers”. In: *Journal of Chemical Technology and Biotechnology* October 2013 (2014).
- [21] Ruth Huey et al. “A semiempirical free energy force field with charge-based desolvation.” In: *Journal of computational chemistry* 28.6 (Apr. 2007), pp. 1145–52.
- [22] Mwafaq Ibdah et al. “A Novel Mg<sup>2+</sup>-dependent O-Methyltransferase in the Phenylpropanoid Metabolism of *Mesembryanthemum crystallinum*”. In: *Journal of Biological Chemistry* 278.45 (Nov. 2003), pp. 43961–43972.

- [23] PD Josephy, T Eling, and RP Mason. “The horseradish peroxidase-catalyzed oxidation of 3, 5, 3', 5'-tetramethylbenzidine. Free radical and charge-transfer complex intermediates.” In: *Journal of Biological Chemistry* 257 (1982), pp. 3669–3675.
- [24] Wolfgang Kabsch. “Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants”. In: *Journal of Applied Crystallography* 26.pt 6 (Dec. 1993), pp. 795–800.
- [25] Wolfgang Kabsch. “Integration, scaling, space-group assignment and post-refinement”. In: *Acta Crystallographica Section D: Biological Crystallography* 66.2 (Feb. 2010), pp. 133–144.
- [26] Wolfgang Kabsch. “Xds”. In: *Acta Crystallographica Section D: Biological Crystallography* 66.2 (Feb. 2010), pp. 125–132.
- [27] Youichi Kondou et al. “cDNA Libraries”. In: *Methods in Molecular Biology* 729 (2011), pp. 183–197.
- [28] Jakub G. Kopycki et al. “Biochemical and Structural Analysis of Substrate Promiscuity in Plant Mg<sup>2+</sup>-Dependent O-Methyltransferases”. In: *Journal of Molecular Biology* 378.1 (Apr. 2008), pp. 154–164.
- [29] Ulrich K Laemmli. “Cleavage of structural proteins during the assembly of the head of bacteriophage T4.” In: *Nature* 227.5259 (1970), pp. 680–685.
- [30] Tom J. Mabry, K. R. Markham, and M. B. Thomas. *The Systematic Identification of Flavonoids*. Berlin, Heidelberg: Springer Berlin Heidelberg, 1970.
- [31] Savvas C Makrides and Savvas C Makrides. “Strategies for Achieving High-Level Expression of Genes in Escherichia coli”. In: *Microbiological reviews* 60.3 (1996), pp. 512–538.
- [32] Airlie J. McCoy. “Solving structures of protein complexes by molecular replacement with Phaser”. In: *Acta Crystallographica Section D: Biological Crystallography* 63.1 (Jan. 2006), pp. 32–41.
- [33] Airlie J. McCoy et al. “Phaser crystallographic software”. In: *Journal of Applied Crystallography* 40.4 (Aug. 2007), pp. 658–674.
- [34] Edoardo Mentasti and Ezio Pelizzetti. “Reactions between iron(III) and catechol (o-dihydroxybenzene). part I. Equilibria and kinetics of complex formation in aqueous acid solution”. In: *Journal of the Chemical Society, Dalton Transactions* 23 (Jan. 1973), p. 2605.
- [35] Garrett M Morris et al. “AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.” In: *Journal of computational chemistry* 30.16 (Dec. 2009), pp. 2785–91.

- [36] Garib N. Murshudov, Alexei a. Vagin, and Eleanor J. Dodson. “Refinement of macromolecular structures by the maximum-likelihood method”. In: *Acta Crystallographica Section D: Biological Crystallography* 53.3 (May 1997), pp. 240–255.
- [37] Janet Newman. “Novel buffer systems for macromolecular crystallization”. In: *Acta Crystallographica Section D: Biological Crystallography* 60.3 (2004), pp. 610–612.
- [38] Novagen. *pET System Manual*. 11th ed. Darmstadt: EMD Chemicals, 2010.
- [39] Ira Palmer and Paul T. Wingfield. “Preparation and extraction of insoluble (Inclusion-body) proteins from *Escherichia coli*”. In: *Current Protocols in Protein Science* 1.SUPPL.70 (Nov. 2012), Unit6.3.
- [40] Harold R. Powell. “The Rossmann Fourier autoindexing algorithm in MOS-FLM”. In: *Acta Crystallographica Section D: Biological Crystallography* 55.10 (1999), pp. 1690–1695.
- [41] R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing. Vienna, Austria, 2015.
- [42] Randy J. Read. “Pushing the boundaries of molecular replacement with maximum likelihood.” en. In: *Acta Crystallographica. Section D: Biological crystallography* 57.Pt 10 (Jan. 2001), pp. 1373–1382.
- [43] M. G. Rossmann and D. M. Blow. “The detection of sub-units within the crystallographic asymmetric unit”. In: *Acta Crystallographica* 15.1 (Jan. 1962), pp. 24–31.
- [44] Michael G. Rossmann. “Molecular replacement - Historical background”. In: *Acta Crystallographica - Section D Biological Crystallography* 57.10 (Sept. 2001), pp. 1360–1366.
- [45] Rainer Rudolph and Hauke Lilie. “In vitro folding of inclusion body proteins”. In: *FASEB Journal* 10 (1996), pp. 49–56.
- [46] Bernhard Rupp. *Biomolecular Crystallography: Principles, Practice, and Application to Structural Biology*. 1st ed. New York: Garland Science, 2009, p. 800.
- [47] J Sambrook and D W Russell. *Molecular Cloning: A Laboratory Manual*. 3rd ed. Cold Spring Harbor (NY, USA): Cold Spring Harbor Laboratory Press, 2001.
- [48] N. Schweigert, a. J B Zehnder, and R. I L Eggen. “Chemical properties of catechols and their molecular modes of toxic action in cells, from microorganisms to mammals”. In: *Environmental Microbiology* 3.2 (2001), pp. 81–91.

- <sup>1</sup> [49] Stanley K. Shapiro and Dimis J. Ehninger. “Methods for the analysis and  
<sup>2</sup> preparation of adenosylmethionine and adenosylhomocysteine”. In: *Analyti-  
<sup>3</sup> cal Biochemistry* 15.2 (May 1966), pp. 323–333.
- <sup>4</sup> [50] Sigma-Aldrich. *Technical Bulletin no. 2003-03: freezing of microbial samples  
<sup>5</sup> prior to testing*. Parenteral Drug Association. 2003.
- <sup>6</sup> [51] F William Studier. “Protein production by auto-induction in high density  
<sup>7</sup> shaking cultures.” In: *Protein expression and purification* 41.1 (May 2005),  
<sup>8</sup> pp. 207–234. arXiv: NIHMS150003.
- <sup>9</sup> [52] Oleg Trott and Arthur J Olson. “AutoDock Vina: improving the speed and  
<sup>10</sup> accuracy of docking with a new scoring function, efficient optimization,  
<sup>11</sup> and multithreading.” In: *Journal of computational chemistry* 31.2 (Jan. 2010),  
<sup>12</sup> pp. 455–61.
- <sup>13</sup> [53] Alexei a. Vagin et al. “REFMAC5 dictionary: Organization of prior chemical  
<sup>14</sup> knowledge and guidelines for its use”. en. In: *Acta Crystallographica Section  
<sup>15</sup> D: Biological Crystallography* 60.12 I (Nov. 2004), pp. 2184–2195.
- <sup>16</sup> [54] Thomas Vogt. “Regiospecificity and kinetic properties of a plant natural  
<sup>17</sup> product O-methyltransferase are determined by its N-terminal domain”. In:  
<sup>18</sup> *FEBS Letters* 561.1-3 (Mar. 2004), pp. 159–162.
- <sup>19</sup> [55] Melissa Swope Willis et al. “Investigation of protein refolding using a frac-  
<sup>20</sup> tional factorial screen: a study of reagent effects and interactions.” In: *Protein  
<sup>21</sup> Science* 14.7 (2005), pp. 1818–1826.
- <sup>22</sup> [56] Martyn D. Winn et al. “Overview of the CCP4 suite and current develop-  
<sup>23</sup> ments”. In: *Acta Crystallographica Section D: Biological Crystallography* 67.4  
<sup>24</sup> (Apr. 2011), pp. 235–242.

# <sup>1</sup> Acronyms

<sup>2</sup> **Å** Ångström, 0.1 nm

<sup>3</sup> **AC-9** anthracene-9-carboxylic acid 20

<sup>4</sup> **ATP** adenosine triphosphate 20

<sup>5</sup> **BisTris** 2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol

<sup>6</sup> **B-PER** bacterial protein extraction reagent

<sup>7</sup> **CCP4** Collaborative Computational Project No. 4 22, 23

<sup>8</sup> **CD** circular dichroism 10

<sup>9</sup> **COMT** catechol O-methyl transferase 13

<sup>10</sup> **Coot** Crystallographic Object-Oriented Toolkit 23

<sup>11</sup> **CV** column volumes

<sup>12</sup> **DoE** design of experiments 18

<sup>13</sup> **DTT** dithiothreitol; (2*S*,3*S*)-1,4-bis(sulfanyl)butane-2,3-diol

<sup>14</sup> **EDTA** ethylenediaminetetraacetic acid 15, 17, 18, 26

<sup>15</sup> **FFD** fractional factorial design vii, 18, 19

<sup>16</sup> **FPLC** fast protein liquid chromatography 17, 28

<sup>17</sup> **FT** Fourier transformation 22

<sup>18</sup> **GdmCl** guanidinium hydrochloride

<sup>19</sup> **GFP** green fluorescent protein 23

<sup>20</sup> **GOD** glucose oxidase 24, 48

<sup>21</sup> **GSH** glutathione,  $\gamma$ -L-glutamyl-L-cysteinylglycine 18, 24, 26

<sup>22</sup> **GSSG** glutathione disulfide 18

<sup>23</sup> **HEPES** 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid

<sup>24</sup> **HIC** hydrophobic interaction chromatography 28

<sup>25</sup> **HPLC** high-performance liquid chromatography 13, 20, 26, 29

<sup>26</sup> **HRP** horseradish peroxidase 24

- <sup>1</sup> **IB** inclusion body 17, 19
- <sup>2</sup> **IEX** ion exchange chromatography 20
- <sup>3</sup> **IMAC** immobilized metal affinity chromatography
- <sup>4</sup> **IPB** Leibniz-Institute of Plant Biochemistry
- <sup>5</sup> **IPTG** isopropyl-D-thiogalactopyranosid 14, 16, 17
- <sup>6</sup> **ITC** Isothermal Titration Calorimetry 28, 48
- <sup>7</sup> **LB** lysogeny broth 12, 13, 16
- <sup>8</sup> **MES** 2-(*N*-morpholino)ethanesulfonic acid
- <sup>9</sup> **MLU** Martin-Luther-Universität
- <sup>10</sup> **MMT** L-malic acid/MES/Tris 6, 28
- <sup>11</sup> **MR** molecular replacement
- <sup>12</sup> **MTP** micro-titer plate 21–24, 48
- <sup>13</sup> **MW** molecular weight 15
- <sup>14</sup> **MWCO** molecular weight cut-off
- <sup>15</sup> **NADES** natural deep eutectic solvent vii, 7, 21, 46
- <sup>16</sup> **NPS** nitrogen, phosphate, sulfate buffer
- <sup>17</sup> **NTA** nitrilo triacetic acid 17
- <sup>18</sup> **O-MT** *O*-methyl transferase 24, 26, 29
- <sup>19</sup> **PAGE** polyacrylamide gel electrophoresis 14, 15, 19, 20, 28
- <sup>20</sup> **PBS** phosphate buffered saline 14, 19, 23
- <sup>21</sup> **PCH** propane-1,2-diol/choline chloride,NADES-mixture 21
- <sup>22</sup> **PCR** polymerase chain reaction 10, 11
- <sup>23</sup> **PDA** photo diode array 29
- <sup>24</sup> **PDB** Protein Data Base 22, 23
- <sup>25</sup> **PFOMT** phenylpropanoid and flavonoid *O*-methyl transferase 13, 16, 21–24, 28, 48
- <sup>26</sup> **PHENIX** Phyton-based Hierarchial Environment for Integrated Xtallography 23
- <sup>27</sup> **PMSF** phenylmethanesulfonylfluoride
- <sup>28</sup> **RT** room temperature
- <sup>29</sup> **SAE** *S*-adenosyl-L-ethionine, (2*S*)-2-amino-4-[[[(2*S*,3*S*,4*R*,5*R*)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-ethylsulfonio]butanoat 20, 21
- <sup>30</sup>
- <sup>31</sup> **SAH** *S*-adenosyl-L-homocysteine 18, 26
- <sup>32</sup> **SAM** *S*-adenosyl-L-methionine 20, 24, 26, 32
- <sup>33</sup> **SAMS** *S*-adenosylmethionine synthase 20
- <sup>34</sup> **SDS** sodium dodecylsulfate 7, 14, 15, 19, 20, 28
- <sup>35</sup> **SOMT-2** soy *O*-methyl transferase 13, 16–20, 28

- <sup>1</sup> **SSG** succinate/sodium phosphate/glycine 7
- <sup>2</sup> **TB** terrific broth 13
- <sup>3</sup> **TCA** trichloro acetic acid 14, 15, 19, 26, 28
- <sup>4</sup> **Ti-plasmid** tumor inducing plasmid 8, 48
- <sup>5</sup> **Tris** tris(hydroxymethyl)-aminomethane
- <sup>6</sup> **U** enzyme unit; measure for enzymatic activity (1 U = 1 μmole/min = 1/60 μkat)
- <sup>7</sup> **UV/VIS** ultra violet/visible (light spectrum) 20, 29
- <sup>8</sup> **V** volume
- <sup>9</sup> **ZYP** N-Z-amine, yeast extract, phosphate 16, 48

# <sup>1</sup> Glossary

<sup>2</sup> **GOD** Glucose oxidase is an enzyme.... <sup>45</sup>

<sup>3</sup> **Isothermal Titration Calorimetry (ITC)** Fill in description here <sup>46</sup>

<sup>4</sup> **MTP** Micro-titer plate. Small format rectangular plastic plate containing wells  
<sup>5</sup> to allow for storage of multiple small samples or the containment multiple  
<sup>6</sup> simultaneous reactions. Typical sizes include 24, 96 and 384-wells <sup>46</sup>

<sup>7</sup> **PFOMT** Phenylpropanoid and flavonoid O-methyl transferase from *Mesembryan-*  
<sup>8</sup> *themum crystallinum*, which was first described by Ibdah et al. in 2003 [22]  
<sup>9</sup> <sup>46</sup>

<sup>10</sup> **Ti-plasmid** Commonly found plasmids in *A. tumefaciens* and *A. rhizogenes* that  
<sup>11</sup> confer virulence <sup>47</sup>

<sup>12</sup> **ZYP-5052** Autoinduction medium developed by Studier [51]. The naming stems  
<sup>13</sup> from the components N-Z-amine, yeast extract and *phosphate*. The numbering  
<sup>14</sup> designates the composition; e.g. 5052 refers to 0.5 % glycerol, 0.05 % glucose and  
<sup>15</sup> 0.2 % lactose. <sup>47</sup>